Zentalis Pharmaceuticals Inc
ZNTL
Get informed when a big investor buys or sells
+ FollowMarket Cap$157.32M
Close$
$-0.05
102.3% downside
Current Fair Value
102.3% downsideOvervalued by 102.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $157.32 Million |
|---|---|
| Enterprise Value | $166.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 1.94 |
| Outstanding Shares | 70,264,000 |
Return
| Return on Equity | -121.76% |
|---|---|
| Return on Assets | -81.22% |
| Return on Invested Capital | -100.99% |
Valuation & Multiples
| P/E Ratio | -0.9 |
|---|---|
| PEG | -0.48 |
| Price to Sales | - |
| Price to Book Ratio | 1.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.93 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0430▼ 430.32% |
|---|---|
| Total Calls | 593,000▲ 4461.54% |
| Total Puts | 25,500▼ 54.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 67.68%▲ 10.29% |
|---|---|
| Total Invested | $229.73M▲ 144.11% |
| Investors Holding | 123▲ 19.00% |
ESG Score
No data
About Zentalis Pharmaceuticals Inc
124 employeesZentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeli...